Contraline Inc.
Contraline is a Charlottesville-based company working at the forefront of reproductive medicine.
CORE INFO
Contraline Inc. is a biotechnology company developing male contraceptive solutions, including a topical gel and a reversible implant, aimed at providing safe and effective options for men and couples.
- Contraline recently secured $92.5 million in a Series B funding round, co-led by BVF Partners L.P. and RA Capital Management, with participation from GV, Lumira Ventures, and Invus.businesswire.com
- The company's NES/T Gel has completed a global Phase 2b clinical trial with 462 couples, showing promising results in efficacy and user acceptability.businesswire.com
WHY WE WOULD WORK AT CONTRALINE INC.
Empower Reproductive Health
Join a mission-driven team dedicated to providing innovative male contraceptive solutions that enhance personal freedom and control in reproductive health.
Cutting-Edge Technology
Work with groundbreaking products like NES/T Gel and the ADAM™ implant, pushing the boundaries of male contraception through advanced biotechnology.
Collaborative Team Culture
Be part of a growing team of 27 passionate professionals, fostering a collaborative environment that values innovation and creativity.
Strong Financial Backing
Benefit from the security of a well-funded company, having raised $113.98 million, including a recent $92.5 million Series B round to fuel growth.
Clinical Success Stories
Contribute to impactful clinical trials, including a successful Phase 2b trial with 462 couples, showcasing the efficacy and acceptability of NES/T Gel.
Innovative Work Environment
Engage in a culture that prioritizes innovation, encouraging new ideas and solutions in the rapidly evolving field of male contraception.
MARKET AND TRACTION
TOTAL FUNDING
✦ KEY METRICTEAM GROWTH
✦ KEY METRICCLINICAL TRIAL SUCCESS
✦ KEY METRICMARKET POSITION
MISSION STATEMENT
PRODUCT AND TECH
NES/T Gel
NES/T Gel is an investigational topical gel that combines synthetic progestin segesterone acetate with testosterone to suppress sperm production while maintaining physiological testosterone levels. This innovative product has completed a Phase 2b clinical trial with promising results, paving the way for its anticipated Phase 3 development in 2027.
ADAM™ Implant
ADAM™ is a long-lasting, non-hormonal, and reversible contraceptive implant currently in clinical trials. This innovative technology aims to provide an alternative contraceptive solution that does not rely on hormonal methods, expanding options for male contraception.
Hydrogel-based Technology
Contraline is developing hydrogel-based implants as part of its contraceptive solutions. This technology is crucial for creating effective, long-lasting, and reversible male contraceptive options that can integrate seamlessly into users' lives.
Clinical Development Expertise
Contraline's expertise in clinical development is demonstrated through its successful Phase 2b trial for NES/T Gel and ongoing trials for ADAM™. This experience is vital for advancing innovative male contraceptive solutions and ensuring their safety and efficacy.
Funding for Innovation
With a total of $113.98 million raised across multiple funding rounds, including a recent $92.5 million Series B, Contraline is well-positioned to advance its research and development efforts. This financial backing supports the company's mission to innovate in male reproductive health.